Catheter Precision to Attend and Participate in the 13th Internation Symposium on Left Atrial Appendage
Rhea-AI Summary
Catheter Precision (VTAK) has announced its participation in the 13th International Symposium on Left Atrial Appendage (ISLAA) taking place on February 7th and 8th, 2025, in Austin, Texas. The symposium is a multi-specialty cardiovascular educational event focusing on left atrial appendage science.
The program will be managed by leading physicians from prestigious institutions including The Kansas City Heart Rhythm Institute, Texas Cardiac Arrhythmia Institute, Los Robles Medical Center, Mayo Clinic, and Mt. Sinai. The event features hands-on demonstrations and product education for electrophysiology fellows.
Catheter Precision will showcase LockeT, their solution for closing large access sites after LAA procedures. CEO David Jenkins highlighted that LockeT offers a safe and effective option for wound closure, enabling cost reduction and same-day hospital discharge.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, VTAK declined 0.26%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
FORT MILL, S.C., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced their attendance at the 13th International Symposium on Left Atrial Appendage (ISLAA). ISLAA will take place on February 7th and 8th, 2025 in Austin, Texas.
The ISLAA meeting is a multi-specialty cardiovascular educational symposium on the frontier science of left atrial appendage (LAA). Over two days, course directors and leading physicians from The Kansas City Heart Rhythm Institute, Texas Cardiac Arrhythmia Institute, Los Robles Medical Center, Mayo Clinic and Mt. Sinai will manage the program and content.
In addition, the ISLAA meeting provides a unique opportunity for hands-on demonstrations and product education for electrophysiology fellows. Catheter Precision will be participating in these sessions to provide fellows an opportunity to try LockeT, ask questions and learn more about the products benefits, which include cost reduction for the hospital and same day hospital discharge.
David Jenkins, CEO of Catheter Precision, said, “ISLAA is a unique meeting because it is a small group of physicians that perform a niche procedure. These left atrial appendage procedures require the use of a large-bore catheter, meaning that the access site is large. Closing these larger wounds can be difficult, but LockeT provides a safe and effective option for closing these large access sites after LAA procedures.”
About LockeT
Catheter Precision’s LockeT is a suture retention device intended to assist in wound closure after percutaneous venous punctures. LockeT is a Class 1 device registered with the FDA.
About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risk and uncertainties. Forward-looking statements can be identified by words such as “believe,” “anticipate,” “may,” “might,” “can,” “could,” “continue,” “depends,” “expect,” “expand,” “forecast,” “intend,” “predict,” “plan,” “rely,” “should,” “will,” “may,” “seek,” or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, but are not limited to, statements regarding product evaluations at the hospital, and that the purchase order indicates that the hospital and its staff see the value and benefits that LockeT can bring and expectations regarding LockeT evaluations in the coming weeks. The Company’s expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties included under the caption “Risk Factors” in the Company’s Form 10-K filed with the SEC and available at www.sec.gov.
The forward-looking statements included in this communication are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
CONTACTS:
At the Company
David Jenkins
973-691-2000
info@catheterprecision.com
# # #
FAQ
When and where is Catheter Precision (VTAK) attending the ISLAA symposium?
What product will VTAK demonstrate at ISLAA 2025?
What are the key benefits of VTAK's LockeT product?
Which medical institutions are managing the ISLAA 2025 program where VTAK is participating?
How will VTAK's participation at ISLAA 2025 benefit electrophysiology fellows?
